Tine Jerman

Tine Jerman

Auto-generated profile, based on publicly available information

Tine Jerman

Department of Cervical Cancer Screening, Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
UIUrška Ivanuš
Urška Ivanuš
TJTine Jerman
Tine Jerman
UOUrška Gašper Oblak
Urška Gašper Oblak
LMLeon Meglič
Leon Meglič
MFMojca Florjančič
Mojca Florjančič
MGMojca Gobec
Mojca Gobec
The COVID-19 pandemic threatens the impact of cervical cancer screening and global cervical cancer elimination goals. As cervical cancer screening programmes were adjusting to the new situation, we evaluated the intensity, quality, and outcomes of cervical cancer screening in Slovenia in the first seven months of the pandemic. Historical observational study on data from a population-based cervical cancer screening registry. Number of cervical cytopathology (screening and follow-up), histopathology (diagnostic procedures, invasive procedures and number of newly diagnosed CIN2+ cases) and HPV test results from the entire Slovenian women population between January 1st and September 30th 2020 were compared to a three-year average of the years 2017–19. A two-month screening lock-down between March 12th and May 8th 2020 resulted in an epidemic deficit of screening (-92%), follow-up (-70%), and HPV triage tests (-68%), as well as invasive diagnostic (-47%) and treatment (-15%) of cervical lesions. Time to diagnosis and treatment did not increase; times to laboratory results fluctuated but stayed within standards. Slovenia has entered the second epidemic intending to add as little as possible to the pandemic deficit of screening smears (-23%) and yearly CIN2+ cases (-10%). Women aged 30–39 were most affected, with the highest pandemic deficit of screening smears (-26%) and yearly CIN2+ cases (-19%). The pandemic has deeply affected all levels of our lives. New vulnerable groups and inequalities have emerged that require recognition and action. To prevent long-term increases in the cervical cancer burden due to the COVID-19 pandemic, it is crucial that organised screening is maintained and monitored in settings where it can be safely and comprehensively provided. None.

28 December 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
AIAbyan Irzaldy
Abyan Irzaldy
TJTine Jerman
Tine Jerman
IKInge M.C.M. de Kok
Inge M.C.M. de Kok
JHJan A.C. Hontelez
Jan A.C. Hontelez
HKHarry J. de Koning
Harry J. de Koning
UIUrška Ivanuš
Urška Ivanuš
HPV vaccination is most efficacious in preventing cervical cancer and its precursors when administered during preadolescence. Because in Slovenia women are invited for cytology screening from age 20, women targeted for preadolescent HPV vaccination have been screening-eligible since 2018. We aim to assess the impact of preadolescent HPV vaccination programme on cytology screening performance and CIN2+ incidence. This is a cohort study using data from Slovenia's cervical screening registry. We compared the incidence of high-grade lesions (CIN2 or worse) between women in the first vaccine-targeted birth cohort (1998–2001) and in the latest non-vaccine-targeted birth cohort (1994–1997). We calculated the Incidence Rate Ratio (IRR) of CIN2+ using Poisson regression. To identify a possible shift in the harms-benefits ratio of screening, we compared the following screening performance indicators using chi-square tests: colposcopy referral rate (CRR), positive predictive value (PPV) of low-grade and high-grade results, and CIN2+ detection rate. The annual quadrivalent vaccine coverage in vaccine-targeted cohort was between 48.7% and 55.2%. The CIN2+ incidence was substantially lower in vaccine-targeted cohort (IRR 0.58 95% CI 0.49–0.69). Screening indicators were significantly lower for the vaccine-targeted cohort: direct CRR (0.47% [118/25,185] vs. 0.68% [206/30,181]), PPV (26.8% [30/112] vs. 39.0% [76/195]), and CIN2+ detection rate (0.31% [79/25,185] vs. 0.55% [165/30,181]) (p < 0.05). Even under imperfect vaccination coverage of around 50%, CIN2+ incidence in the vaccine-targeted cohort was observed to be 42% lower. Furthermore, the harms-benefits ratio of cervical screening deteriorates, marked by lower PPV and detection rate. This warrants an adaptation in screening algorithms in vaccinated cohorts. European Union Horizon 2020.